Sun Life Financial INC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 25,478.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,581 shares of the company’s stock after acquiring an additional 3,567 shares during the period. Sun Life Financial INC’s holdings in Zoetis were worth $223,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after acquiring an additional 230 shares during the last quarter. Guardian Life Insurance Co. of America boosted its stake in shares of Zoetis by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock valued at $102,000 after purchasing an additional 13 shares in the last quarter. Point72 Asia Hong Kong Ltd purchased a new stake in shares of Zoetis in the 1st quarter valued at $111,000. Harfst & Associates Inc. boosted its stake in shares of Zoetis by 16.1% in the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after purchasing an additional 260 shares in the last quarter. Finally, Almanack Investment Partners LLC. purchased a new stake in shares of Zoetis in the 2nd quarter valued at $119,000. Institutional investors and hedge funds own 93.20% of the company’s stock.

Zoetis Inc. (NYSE:ZTS) traded up 0.78% during midday trading on Monday, reaching $64.26. The company’s stock had a trading volume of 398,003 shares. The firm has a market cap of $31.43 billion, a price-to-earnings ratio of 36.33 and a beta of 1.02. The company’s 50-day moving average is $62.44 and its 200 day moving average is $59.64. Zoetis Inc. has a 12-month low of $46.86 and a 12-month high of $65.83.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, hitting the consensus estimate of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The firm had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same period in the prior year, the business posted $0.49 earnings per share. The company’s revenue for the quarter was up 5.0% on a year-over-year basis. Equities analysts forecast that Zoetis Inc. will post $2.34 earnings per share for the current year.

ZTS has been the topic of several recent research reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $75.00 target price on shares of Zoetis in a report on Tuesday, September 26th. BidaskClub cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 20th. Stifel Nicolaus reissued a “buy” rating and issued a $65.00 price target on shares of Zoetis in a research note on Friday, September 1st. Piper Jaffray Companies set a $73.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research note on Friday, August 25th. Finally, Cowen and Company set a $70.00 price target on shares of Zoetis and gave the company a “buy” rating in a research report on Thursday, August 24th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company. Zoetis currently has an average rating of “Buy” and an average target price of $65.76.

ILLEGAL ACTIVITY WARNING: This piece was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/02/sun-life-financial-inc-acquires-3567-shares-of-zoetis-inc-zts.html.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.